

MEDICAL POLICY - 1.01.536

Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring

Ref. Policy: MP-068

Effective Date: June 1, 2024

24 RELATED MEDICAL POLICIES:

Last Revised: May 24, 2024

Replaces: N/A

None

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY

Clicking this icon returns you to the hyperlinks menu above.

Introduction

Warfarin is a type of drug known as a blood thinner. It is used to help prevent blood clots. For people taking warfarin, prothrombin time/international normalized ratio (PT/INR) is a portable testing device that can be used in the home to measure the time it takes for a person's blood to clot. This policy describes when home prothrombin time/international normalized ratio (PT/INR) monitoring may be considered medically necessary.

Note:

The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Service	Medical Necessity
Home prothrombin	Home PT/INR monitoring devices may be considered
time/international	medically necessary for patients on warfarin needing long-

Service	Medical Necessity
Service normalized ratio (PT/INR) monitoring	term (> 6 months) or life-long coagulation for any of the following conditions: • Mechanical heart valves • Chronic atrial fibrillation • Venous thromboembolism inclusive of deep vein thrombosis (DVT) and pulmonary embolism • Ventricular Assist Devices (VAD) • Hypercoagulable states AND • All of the following requirements have to be met for home PT/INR monitoring of a patient: • The device must be Food and Drug Administration - approved • The patient must have been anticoagulated for at least 3 months prior to the use of the home PT/INR device • The patient must undergo a documented face-to-face educational program on anticoagulation management demonstrating the correct use of the device prior to its use in the home • The patient continues to correctly use the device for anticoagulation therapy following the initiation of home monitoring which is supported with documentation • Self-testing with the device should not occur more frequently than once a week • Only one provider may bill the review, interpretation and management of this service per period of four billable tests and this should be the ordering physician (G0250)
	Note: See Related Information below for Limitations

Coding



Code	Description
СРТ	
93792	Patient/caregiver training for initiation of home international normalized ratio (INR) monitoring under the direction of a physician or other qualified health care professional, face-to-face, including use and care of the INR monitor, obtaining blood sample, instructions for reporting home INR test results, and documentation of patient's/caregiver's ability to perform testing and report results
93793	Anticoagulant management for a patient taking warfarin, must include review and interpretation of a new home, office, or lab international normalized ratio (INR) test result, patient instructions, dosage adjustment (as needed), and scheduling of additional test(s), when performed
HCPCS	
G0248	Demonstration, prior to initiation of home INR monitoring, for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria, under the direction of a physician; includes: face-to-face demonstration of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient's ability to perform testing and report results
G0249	Provision of test materials and equipment for home INR monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests
G0250	Physician review, interpretation, and patient management of home INR testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; testing not occurring more frequently than once a week; billing units of service include 4 tests
ICD-10 Diagnosis Code	es – Covered if Selection Criteria are Met
D68.51-D68.62	Primary hypercoagulable state
126.01-126.99	Pulmonary embolism (acute)
127.82	Chronic pulmonary embolism
148.0-148.21	Chronic atrial fibrillation (persistent and paroxysmal)
180.00-180.9	Phlebitis and thrombophlebitis (including deep vein thrombosis)
I82.0-I82.1	Budd-Chiari syndrome / Thrombophlebitis migraines
I82.211	Chronic embolism and thrombosis of superior vena cava
182.221	Chronic embolism and thrombosis of inferior vena cava



Code	Description
182.291	Chronic embolism and thrombosis of other thoracic veins
182.3	Embolism and thrombosis of renal vein
182.401	Acute embolism and thrombosis of unspecified deep veins right lower extremity
182.402	Left lower extremity
182.403	Bilateral lower extremity
182.409	Unspecified lower extremity
I82.501-I82.5Z9	Chronic embolism and thrombosis of lower extremity (deep) veins
I82.701-I82.729	Chronic embolism and thrombosis of upper extremity veins
I82.A21-I82.A29	Chronic embolism and thrombosis of axillary vein
I82.B21-I82.B29	Chronic embolism and thrombosis of subclavian vein
I82.C21-I82.C29	Chronic embolism and thrombosis of internal jugular vein
I82.811-I82.819	Embolism and thrombosis of other specified veins
182.891	Chronic embolism and thrombosis of other specified veins
Z95.2	Presence of prosthetic heart valve
Z79.01	Long-term (current) use of anticoagulants

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Limitations

- Porcine valves
- Poor eyesight with no caregiver
- Memory impairment
- Difficulty with motor coordination or manual dexterity



History of noncompliance

Evidence Review

Background

The Centers for Medicare and Medicaid Services (CMS) provide an overview on the use of the International Normalized Ratio (INR) or prothrombin time (PT) and how it allows physicians to determine the level of anticoagulation in a patient independent of the laboratory reagents used. PT is the standard measurement for reporting the blood's clotting time. The INR is the ratio of the patient's PT (extrinsic or tissue-factor coagulation pathway) compared to the mean PT for a group of normal individuals.

Patient self-testing and self-management through the use of a home INR monitor may be used to improve the time in therapeutic rate (TTR) for select groups of patients. Increased TTR leads to improved clinical outcomes and reductions in thromboembolic and hemorrhagic events. Warfarin (also prescribed under other trade names, e.g., Coumadin) is a self-administered, oral anticoagulant (blood thinner) medication that affects the vitamin K-dependent clotting factors II, VII, IX and X. A PT/INR monitoring system is a portable testing device that includes a finger-stick and a Food and Drug Administration-cleared meter that measures the time it takes for a person's blood plasma to clot.

There are at least three sites/methods for managing warfarin anticoagulation:

- 1. Physician office-based testing and management
- 2. Anticoagulation clinics
- 3. Home PT/INR monitoring with patient reporting or physician-directed self-management

References

 Centers for Medicare and Medicaid Services (CMS): CMS Manual System-Pub 100-4 Medicare Claims Processing Transmittal 1562. Issued July 25, 2008. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R1562CP.pdf. Last accessed May 17, 2024.

- Centers for Medicare and Medicaid Services (CMS): Decision Memo (CAG-00087R) for Prothrombin Time (INR) Monitor for Home Anticoagulation Management. Issued: March 19, 2008. http://www.cms.gov/medicare-coveragedatabase/details/nca-decision-memo.aspx?NCAId=209&fromdb=true. Last accessed May 17, 2024.
- Centers for Medicare and Medicaid Services (CMS): National Coverage Determination (NCD) No. (190.11) for Home Prothrombin Time /International Normalized Ratio (PT/INR) Monitoring for Anticoagulation Management. Effective Date: March 19, 2008. http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=269&ncdver=2&bc=AgAAgAAAAAAAAAA3d%3d&. Last accessed May 17, 2024.
- Department of Health and Human Services. National Heart, Lung, and Blood Institute: What is Deep Vein Thrombosis? Last Updated: September 19, 2022. http://www.nhlbi.nih.gov/health/health-topics/dvt/. Last accessed May 17, 2024.
- Dignan R, Keech AC, Gebski VJ et al. [Warfarin SMART Investigators]. Is home warfarin self-management effective? Results of the randomized Self-Management of Anticoagulation Research Trail. Int J Cardiol. 2013 Oct; 168(6): 5378-5384. http://www.ncbi.nlm.nih.gov/pubmed/24083884. Last accessed May 17, 2024.
- Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest. 2012 Feb; 141(2_Suppl), 7S-47S. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278060/. Last accessed May 17, 2024.
- Matchar DB, Jacobson A, Dolor R, et al; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608-1620. https://pubmed.ncbi.nlm.nih.gov/20961244/. Last accessed May 17, 2024.

History

Date	Comments
09/16/19	New policy, approved August 13, 2019, effective January 1, 2020. Home prothrombin time/international normalized ratio (PT/INR) monitoring may be considered medically necessary for patients on warfarin needing long-term (> 6 months) or life-long coagulation when criteria are met.
11/01/20	Annual Review, approved October 22, 2020. No changes to policy statement, references updated.
05/01/21	Annual Review, approved April 1, 2021. No changes to policy statement, references updated. Added CPT codes 93792 and 93793.
07/01/22	Annual Review, approved June 13, 2022. No changes to policy statement, references updated.
11/01/23	Annual Review, approved October 23, 2023. No changes to policy statement, references updated.
04/01/24	Annual Review, approved March 25, 2024. No changes to policy statement, references updated.
06/01/24	Interim Review, approved May 24, 2024. Expanded Dx code range for afib to included 148.20 and 148.21.



Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2024 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy only applies to Individual Plans.





Discrimination is Against the Law

LifeWise Health Plan of Washington (LifeWise) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). LifeWise provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-6396, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@LifeWiseHealth.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.isf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx.

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-817-3056 (TTY: 711). 注意:如果您使用繁體中文,您可以免費獲得語言援助服務。請致電 800-817-3056 (TTY: 711)。 CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-817-3056 (TTY: 711). 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-817-3056 (TTY: 711) 번으로 전화해 주십시오. ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-817-3056 (телетайп: 711). РАЦИАЖА: Кипд падзазаlita ка пд Тадаlод, тадагі капд дитаті пд тра serbisyo ng tulong sa wika nang walang bayad. Титаwад sa 800-817-3056 (ТТҮ: 711). УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 800-817-3056 (телетайп: 711).

<u>ATTENTION</u>: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-817-3056 (ATS : 711). <u>UWAGA</u>: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-817-3056 (TTY: 711). <u>ATENÇÃO</u>: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-817-3056 (TTY: 711).

<u>ATTENZIONE</u>: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-817-3056 (TTY: 711). <u>توجه:</u> اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با (TTY: 711) 3056 (TTY: 711 توجه: